Business Wire

PKU: Pre-Clinical Kinetic Data Showing Prolonged Release of Amino Acids Thanks to the Innovative Physiomimic Technology by APR Presented at the 13th ICIEM Congress (September 5th-8th, Rio de Janeiro)


APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, announces today the results of a pre-clinical kinetic study showing a physiological absorption of clinically relevant groups of amino acids (AAs) thanks to the application of the patented Physiomimic™ drug delivery Technology platform. APR’s innovative product is intended to be used for the management of patients with phenylketonuria (PKU).

The results of the investigation indicate that the Physiomimic™ Technology by APR is able to modify the release of clinically relevant AAs by lowering and retarding their absorption profiles if compared to the same mix of amino acids without the application of the technology. Also remarkable is that the kinetic profile of the AAs engineered with the Physiomimic™ Technology resembles that of casein - a reference food protein known to have a prolonged absorption profile.

The study suggests that APR’s advanced formulation of AAs has the potential of contributing to maintain Phenylalanine (“PHE”) levels within the recommended ranges, with less prominent fluctuations of PHE levels over time, thanks to a prolonged release of the AAs in the gut, which is thought to allow a more efficient utilization of the absorbed amino acids, PHE included.
Furthermore, the Physiomimic™ Technology has the ability of remarkably masking their taste and odor, with potential positive consequences on aftertaste for an exceptionally palatable product.

The outcome of the pre-clinical study will be presented in an oral presentation (Gut Microbiota and Human Metabolism” Thursday September 7 th 2017, 11.00-12.30) during the 13th International Congress of Inborn Errors of Metabolism in Rio de Janeiro on September 5 - 8, 2017 (ICIEM 2017). A poster will also illustrate the results of the application of the innovative Physiomimic™ Technology (Attended Poster Session Wednesday September 6 th 17:30 – 20:00) to amino acids for PKU.

“For the first time, the application of a pharmaceutical drug delivery technology platform to a Medical Food leads to a real change in PKU management.” Paolo Galfetti, CEO of Applied Pharma Research, states. “Since data show that there are still open issues in the management of PKU, we developed the Physiomimic™ Technology with the aim of meaningfully contributing to fulfill significant unmet needs of this disorder, providing patients, Healthcare Professionals (HCPs) and care givers with a product that would deliver amino acids in a physiological manner, whilst being very palatable and thus significantly improving patient compliance”.

“The development plan to characterize our innovative product for PKU is robust, - adds Giorgio Reiner, Corporate Director R&D of Applied Pharma Research – “with the next major step being a clinical kinetic study in human volunteers as a proof of concept of the prolonged release of Amino Acids and their consequent physiological absorption. Other pre-clinical studies as well as clinical evidences will reinforce the scientific profile of our proprietary technology and product to help us continue this journey.

On October 5th-8th, APR will also sponsor the 31 st E.S. PKU Conference (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria), in Hell, Norway continuing to contribute to the advancement of the management of this rare disorder.

About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies, in over 70 countries with international sales on a worldwide basis.

About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“PHE”), an essential amino acid found in most protein-containing food. Excessive amounts of PHE in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-PHE) dietetic treatment combined with a daily assumption of low-protein modified foods and Medical Food which provides PHE-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.

For more information about Physiomimic™ Technology, please visit:
For press releases and other company information visit:

Contact information

APR Applied Pharma Research s.a.
Paolo Galfetti; CEO
T: +41 91 6957020
Havas PR Milan - Press Office
Sara Bernabovi, T: +39 02 85457032

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Summer Business with New Shop Feature and High-Performance Tyre Models16.3.2018 17:11Tiedote

Each year, summer trade means great challenges for car garages and tyre dealers. As a result and at just the right time,, the online trade customer shop by Europe’s leading online tyre dealer Delticom, is introducing a new feature intended to make the daily work of the shop’s customers easier: An advice mode is available from now on at When changing from the purchasing to the sales view, the individual end customer prices are displayed instead of the actual purchase prices. In order to use this feature, users of simply have to insert their individual markups for the different item groups. From the markup and the purchase price, the online shop automatically calculates the personal end customer price. The usual purchasing view is also still available. This press release features multimedia. View the full release here: An advice mode immediately helps trade customers use the full pot

Available Now: The Smartphone Made for the Way We Communicate Today, the Galaxy S9 and S9+16.3.2018 15:00Tiedote

Samsung Electronics America, Inc. announced that the new, award-winning Galaxy S9 and Galaxy S9+, which have been recognized by smartphone reviewers worldwide for their best-in-class display, design and camera, are now available for purchase at U.S. wireless network providers and retail stores. The phones come in three colors: Midnight Black, Coral Blue, and the new Lilac Purple. The Galaxy S9 has a suggested retail price of $719.99, while the Galaxy S9+ is available for $839.99. Both unlocked and carrier versions of the Galaxy S9 and Galaxy S9+ are also available for purchase on This press release features multimedia. View the full release here: Designed for the way we communicate today, Samsung's new Galaxy S9 and Galaxy S9+ are available in the U.S. at wireless network providers, retailers and on (Photo: Business Wire) “The Galaxy S9 and S9+ are designed for the visual and social generation—the consum

AccelStor All-Flash Solutions Unlock Data Possibilities for AI and Cloud16.3.2018 12:00Tiedote

AccelStor, an innovative all-flash array (AFA) provider for the big data era, is excited to announce its participation in the upcoming Cloud Expo Europe, taking place from March 21 to 22 at Booth C1850 in the ExCel London exhibition centre. Besides presenting latest all-flash storage solutions breaking through performance and availability barriers for artificial intelligence (AI), virtualization and private cloud, AccelStor will present a live demonstration of its new generation NeoSapphire high availability models, one of the highlights not to be missed this year. This press release features multimedia. View the full release here: AccelStor's new generation NeoSapphire High Availability all-flash array AccelStor NeoSapphire all-flash arrays are highly integrated with virtualization and private cloud platforms, supporting VMware vSphere and OpenStack Cinder. NeoSapphire’s “high availability” series features symmetric active-activ

CONQUEST Group Announced the Expansion of its Asset Management Business with the Appointment of Philippe Taillardat to the Role of Director16.3.2018 12:00Tiedote

Philippe Taillardat brings to CONQUEST over 25 years of Asset Management and Investment Banking experience, primarily in principal investing, financial advisory, equity and debt financing across global infrastructure and sustainable energy sectors. This press release features multimedia. View the full release here: Philippe Taillardat (Photo: CONQUEST Group) Philippe was most recently Co-Head of Infrastructure Investments Europe at First State Investments, which he helped transform into one of the leading billion+ European infrastructure fund manager in core / core+ strategies. Earlier in his career, Philippe held various senior banker and investment roles at Amundi, Credit Agricole CIB, Credit Suisse, AXA and BNP Paribas. Frédéric Palanque, Managing Director of CONQUEST Group, said, "We are delighted to welcome such a recognized professional. CONQUEST is trusted for providing value-added advice in complex and highly confidential

Westinghouse Completes First Major Decommissioning Work at a Nordic Commercial Nuclear Reactor16.3.2018 11:45Tiedote

Westinghouse Electric Company announced today that it has completed a major decommissioning project at the former Barsebäck nuclear power plant in Skåne, Sweden. Barsebäck Unit 2 ceased operation in 2005 and decommissioning work began in August 2016. Westinghouse’s scope of work included the underwater segmentation and packaging of the reactor vessel internals, as well as the upfront engineering studies and equipment manufacturing and qualification. “Westinghouse is proud to deliver this major decommissioning project on time and on budget,” said Yves Brachet, Westinghouse senior vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “Our global expertise in this area will help our customers in the Nordic region to safely manage a variety of end-of-life opportunities for commercial nuclear power plants.” Leadership at Barsebäck Kraft AB (BKAB) is equally satisfied with this successful initial step of the first dismantling of a commercial nuclear power

Lighting Manufacturer LTS Licht & Leuchten, Part of the Fargerhult Group, to Offer Selected Spot- & Downlights with Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs16.3.2018 11:02Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for selected luminaires of LTS Licht & Leuchten GmbH, a German manufacturer of high-quality luminaires for hospitality, retail, and office applications. This press release features multimedia. View the full release here: LTS Jett 100 spotlights equipped with SunLike LED technology (Photo: Business Wire) LTS has adopted SunLike natural spectrum LEDs for selected products, including the Jett 100 and CSA 60 spotlights. A series of spotlights with a discreet and individual appearance, and clear, straightforward design lines, Jett spotlights harmoniously blend in with any type of retail application. The high color rendering and superior luminous intensity of these spotlights enable lighting designers to achieve accentuated ar

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme